JNJ Stock Summary and Trading Ideas (Johnson & Johnson | NYSE:JNJ)

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Johnson & Johnson trades on the NYSE stock market under the symbol JNJ.

As of February 10, 2025, JNJ stock price climbed to $154.24 with 4,730,714 million shares trading.

JNJ has a beta of 0.08, meaning it tends to be less sensitive to market movements. JNJ has a correlation of 0.00 to the broad based SPY ETF.

JNJ has a market cap of $371.41 billion. This is considered a Mega Cap stock.

Last quarter Johnson & Johnson reported $23 billion in Revenue and $2.04 earnings per share. This beat revenue expectation by $70 million and exceeded earnings estimates by $.02.

In the last 3 years, JNJ traded as high as $186.69 and as low as $140.68.

The top ETF exchange traded funds that JNJ belongs to (by Net Assets): VTI, VOO, SPY, IVV, VTV.

JNJ has underperformed the market in the last year with a return of +0.7%, while the SPY ETF gained +22.8%. In the last 3 month period, JNJ fell short of the market, returning -0.8%, while SPY returned +1.9%. However, in the most recent 2 weeks JNJ has outperformed the stock market by returning +5.1%, while SPY returned -0.5%.

JNJ support price is $151.22 and resistance is $155.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JNJ shares will trade within this expected range on the day.